Amphastar Pharmaceuticals Management
Management criteria checks 3/4
Amphastar Pharmaceuticals' CEO is Jack Zhang, appointed in Jan 1996, has a tenure of 29.75 years. total yearly compensation is $7.73M, comprised of 11.8% salary and 88.2% bonuses, including company stock and options. directly owns 5.64% of the company’s shares, worth $69.57M. The average tenure of the management team and the board of directors is 11.9 years and 6.3 years respectively.
Key information
Jack Zhang
Chief executive officer
US$7.7m
Total compensation
| CEO salary percentage | 11.83% |
| CEO tenure | 29.8yrs |
| CEO ownership | 5.6% |
| Management average tenure | 11.9yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
After Protracted Sell-Off, Amphastar Looks Like A Value Pick
Sep 23Earnings Working Against Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Share Price
Jul 01
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Stay On Top Of Its Debt
Apr 04Amphastar Pharmaceuticals: A Gradual Strategy
Feb 19These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Reasonably Well
Jan 03Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Prospects Need A Boost To Lift Shares
Dec 16Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 28Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)
Oct 25Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Sep 15Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines
Sep 12
Decisive Acquisitions And Production Innovations Propel Pharma Growth And Market Dominance
Emphasis on proprietary products and strategic acquisitions to enhance market presence and contribute significantly to revenue growth.Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
Aug 27Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 05Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Jul 01Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
May 30Amphastar Pharmaceuticals: Buy When Fear Is Overblown
May 30Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | US$135m |
| Mar 31 2025 | n/a | n/a | US$142m |
| Dec 31 2024 | US$8m | US$915k | US$160m |
| Sep 30 2024 | n/a | n/a | US$158m |
| Jun 30 2024 | n/a | n/a | US$167m |
| Mar 31 2024 | n/a | n/a | US$155m |
| Dec 31 2023 | US$8m | US$898k | US$138m |
| Sep 30 2023 | n/a | n/a | US$135m |
| Jun 30 2023 | n/a | n/a | US$102m |
| Mar 31 2023 | n/a | n/a | US$93m |
| Dec 31 2022 | US$7m | US$1m | US$91m |
| Sep 30 2022 | n/a | n/a | US$77m |
| Jun 30 2022 | n/a | n/a | US$91m |
| Mar 31 2022 | n/a | n/a | US$81m |
| Dec 31 2021 | US$7m | US$898k | US$62m |
| Sep 30 2021 | n/a | n/a | US$36m |
| Jun 30 2021 | n/a | n/a | US$10m |
| Mar 31 2021 | n/a | n/a | US$2m |
| Dec 31 2020 | US$6m | US$898k | US$1m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$4m |
| Mar 31 2020 | n/a | n/a | US$52m |
| Dec 31 2019 | US$6m | US$898k | US$49m |
| Sep 30 2019 | n/a | n/a | US$52m |
| Jun 30 2019 | n/a | n/a | US$53m |
| Mar 31 2019 | n/a | n/a | US$2m |
| Dec 31 2018 | US$6m | US$1m | -US$6m |
Compensation vs Market: Jack's total compensation ($USD7.73M) is above average for companies of similar size in the US market ($USD5.53M).
Compensation vs Earnings: Jack's compensation has been consistent with company performance over the past year.
CEO
Jack Zhang (78 yo)
Dr. Yongfeng Zhang, also known as Jack, Ph D., has been President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive O...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 29.8yrs | US$3.80m | 2.35% $ 28.9m | |
| Co-founder | 29.8yrs | US$7.73m | 5.64% $ 69.6m | |
| CFO, Executive VP of Finance | 11.5yrs | US$2.91m | 0.12% $ 1.5m | |
| Executive VP of Sales | 12.3yrs | US$1.82m | 0.12% $ 1.5m | |
| Senior EVP of Production & EVP of Scientific Affairs | 10.3yrs | US$2.13m | 0.42% $ 5.2m | |
| Senior Vice President of Human Resources & Corporate Communication | 3.2yrs | no data | no data | |
| Executive VP of Regulatory Affairs & Clinical Operations | no data | no data | no data |
Experienced Management: AMPH's management team is seasoned and experienced (11.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 29.8yrs | US$3.80m | 2.35% $ 28.9m | |
| Co-founder | 29.8yrs | US$7.73m | 5.64% $ 69.6m | |
| CFO, Executive VP of Finance | 3.2yrs | US$2.91m | 0.12% $ 1.5m | |
| Executive VP of Sales | 3.2yrs | US$1.82m | 0.12% $ 1.5m | |
| Lead Independent Director | 23.7yrs | US$375.12k | 0.058% $ 715.7k | |
| Independent Director | 4.3yrs | US$340.00k | 0.0058% $ 72.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.3yrs | US$327.64k | 0.040% $ 494.2k |
Experienced Board: AMPH's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 18:28 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amphastar Pharmaceuticals, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Nachman | BMO Capital Markets Equity Research |
| Jason Matthew Gerberry | BofA Global Research |
| Timothy Chiang | Capital One Securities, Inc. |